The SPDR S&P Biotech ETF (XBI) experienced a significant inflow of approximately $738 million, marking a 9.5% increase in outstanding units from 60,120,000 to 65,850,000 within the last week. The inflow indicates heightened investor interest in the biotech sector.
Notable underlying components of XBI include Madrigal Pharmaceuticals (MDGL), which is down about 4.5%, TG Therapeutics (TGTX), down 1.3%, and Alkermes (ALKS), lower by 2.7%. The ETF’s current trading price is $127.30, positioned between its 52-week low of $66.66 and high of $132.09.
XBI’s performance can also be analyzed using its 200-day moving average, which provides insights into its price trends over the past year.
